A three-year follow-up on patients with T2DM on drug therapy in Shihezi communities
10.3969/j.issn.1006-5725.2017.18.037
- VernacularTitle:石河子社区2型糖尿病患者药物治疗3年随访研究
- Author:
Li TIAN
1
;
Xiangyun CHANG
;
Jun LI
;
Xiaoli WANG
;
Xianghui SU
;
Lingyun ZHU
;
Kan SUN
Author Information
1. 石河子大学医学院第一附属医院内分泌科
- Keywords:
type 2 diabetes mellitus;
hypoglycemic scheme;
clinical outcome;
blood glucose con-trol rate
- From:
The Journal of Practical Medicine
2017;33(18):3123-3127
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the changes of the constituent ratio of hypoglycemic scheme and clinical outcomes of patients with type 2 diabetes mellitus(T2DM)in recent three years in Shihezi. Methods The cluster random sampling methods were used to select 300 patients with T2DM who met the standards in November 2012 from 13 communities in Shihezi. The datasets including general demographic information ,treatment and clinical outcomes were collected by following them up for three years. Results From 2012 to 2015,the proportion of pa-tients with oral drugs decreased from 63.5％ to 51％ while increased from 30.8％ to 41.8％ with insulin treatment. For the patients with insulin treatment ,the rate of patients on single drug therapy declined significantly (χ2 =8.77,P<0.05),while significantly increased on insulin combined with oral drug(χ2=-10.27,P<0.01). The incidence of adverse effects increases from 16.8％ to 24.5％. As compared with 2012,blood sugar levels and con-trol rate had no obvious changes in 2015;namely,according to the standard(1),the control rate of blood glucose in 2015 was 41.2％,decreasing 4.0％as compared with 2012,while according to the standard(2),it increasd by 1.4％ from 2012 to 2015(52.9％). The rate of diabetic complications significantly increased from 2012 to 2015. Conclusions Oral drugs are mainly used in the treatment of T2DM in Shihezi communities,whereas the rate of insulin use elevates. The blood glucose control rate,medication safety,and ability to lower the rate of diabetic com-plications need to be improved in T2DM patients in Shihezi communities.
